Hematology NewsLCAR-B38M CAR T therapy appears durable in myelomaDecember 5, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
Oncology PracticePD-L1 expression best predicts response to atezolizumab + nab-paclitaxel for mTNBCDecember 5, 2018Breast CancerImmuno-oncology
Oncology PracticeNo boost in OS with addition of capecitabine for early TNBCDecember 5, 2018Breast Cancer
Hematology News2018: A banner year for hematology drug approvalsDecember 5, 2018Business of MedicineCLLAggressive LymphomasMixed TopicsPractice ManagementLymphoma & Plasma Cell DisordersRare Diseases
Oncology PracticePhase 3 study confirms biosimilarity of PF-05280586 with rituximabDecember 5, 2018Lymphoma & Plasma Cell DisordersAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology NewsFactor IX expression stable at up to 8 years with gene therapyDecember 5, 2018Bleeding DisordersGene Therapy
Oncology PracticeSimilarity of CT-P6 and trastuzumab remain with longer follow-upDecember 5, 2018Breast CancerPractice ManagementBusiness of Medicine
Hematology NewsCLL resistance mechanism to venetoclax identifiedDecember 5, 2018CLLAggressive LymphomasLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersB Cell Lymphoma
Oncology PracticeKATHERINE: T-DM1 doubles HER2-positive invasive disease-free survivalDecember 5, 2018Breast Cancer
Hematology NewsLarge cohort study IDs prognostic factors in thromboangiitis obliteransDecember 5, 2018Mixed TopicsThrombosis
Hematology NewsIn IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remissionDecember 5, 2018AMLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology NewsFLT3 inhibitor moves forward in newly diagnosed AMLDecember 4, 2018AMLLeukemia, Myelodysplasia, Transplantation
Hematology NewsDOAC pause yields favorable outcomes for AF patientsDecember 4, 2018ThrombosisBleeding Disorders
Oncology PracticeEarly intervention initiative cut oncology patient hospitalizationsDecember 4, 2018Practice ManagementBusiness of Medicine
